SARS-CoV-2 Innate Effector Associations and Viral Load in Early Nasopharyngeal Infection

Theodore G Liou; Frederick R Adler; Barbara C Cahill; David R Cox; James E Cox; Garett J Grant; Kimberl E Hanson; Stephen C Hartsell; Nathan D Hatton; My N Helms; Judy L Jensen; Christiana Kartsonaki; Yanping Li; Daniel T Leung; James E Marvin; Elizabeth A Middleton; Sandra M Osburn-Staker; Kristyn A Packer; Salika Mehreen Shakir; Anne B Sturrock; Keith D Tardiff; Kristi J Warren; Lindsey J Waddoups; Lisa J Weaver; Elizabeth Zimmerman; Robert Paine III.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-20223545

Documentos relacionados

  1. SARS-CoV-2 Innate Effector Associations and Viral Load in Early Nasopharyngeal Infection.
  2. SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection.
  3. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
  4. SARS-CoV-2 variants evolve convergent strategies to remodel the host response.
  5. Myeloid dysregulation and therapeutic intervention in COVID-19.
  6. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
  7. Cross protection to SARS-CoV-2 variants in hamsters with naturally-acquired immunity.
  8. COV2Var, a function annotation database of SARS-CoV-2 genetic variation.
  9. All Domains of SARS-CoV-2 nsp1 Determine Translational Shutoff and Cytotoxicity of the Protein.
  10. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.